IDEXX LABORATORIES INC /DE Deferred Tax Liabilities, Deferred Expense, Deferred Policy Acquisition Cost
IDEXX LABORATORIES INC /DE (IDXX) had Deferred Tax Liabilities, Deferred Expense, Deferred Policy Acquisition Cost of $62.64 million as of 2025-12-31, per its 10-K filed 2026-02-20.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Net › Deferred Tax Liabilities, Gross
us-gaap:DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCost · last filed 2026-02-20
- 2025-12-31: Deferred Tax Liabilities, Deferred Expense, Deferred Policy Acquisition Cost $62.64M.
- 2024-12-31: Deferred Tax Liabilities, Deferred Expense, Deferred Policy Acquisition Cost $46.89M.
- 2023-12-31: Deferred Tax Liabilities, Deferred Expense, Deferred Policy Acquisition Cost $39.32M.
- 2022-12-31: Deferred Tax Liabilities, Deferred Expense, Deferred Policy Acquisition Cost $37.22M.
| Period end | Deferred Tax Liabilities, Deferred Expense, Deferred Policy Acquisition Cost |
|---|---|
| 2025-12-31 | $62.64M 10-K · filed 2026-02-20 |
| 2024-12-31 | $46.89M 10-K · filed 2026-02-20 |
| 2023-12-31 | $39.32M 10-K · filed 2025-02-21 |
| 2022-12-31 | $37.22M 10-K · filed 2024-02-22 |
| 2021-12-31 | $37.27M 10-K · filed 2023-02-16 |
| 2020-12-31 | $34.45M 10-K · filed 2022-02-16 |
| 2019-12-31 | $28.52M 10-K · filed 2021-02-12 |
| 2018-12-31 | $24.32M 10-K · filed 2020-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lantheus Holdings, Inc. (LNTH) | United States | $6.510B | 26.31 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |